COVID-19 Clinical Trials

Find COVID-19 Clinical Trials Near You

Assessing the Effects of Coronavirus Disease (COVID-19) on Multiple Organ Systems and Impact on Quality of Life, Functional Capacity and Mental Health

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

The C-MORE study is prospective observational holistic longitudinal study which will characterise the prevalence of multi-organ injury among COVID-19 survivors post hospital discharge and assess its effects on quality of life, exercise tolerance and mental health.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 100
Healthy Volunteers: t
View:

• Participant is willing and able to give informed consent for participation in the study.

• Male or Female, aged 18 years or above.

• Diagnosis of COVID-19 infection confirmed by detection of viral nucleic acid on reverse-transcription Polymerase Chain Reaction (RT-PCR).

• Infection should be of moderate to severe intensity (i.e, patients with clinical signs of pneumonia such as respiratory rate \> 30 breaths/min; or severe respiratory distress; or SpO2 \< 90% (on room air) and admission for \>48 hours.

• Controls: Participants with no serological evidence of previous infection, or active/previous symptoms suggestive of COVID-19, and who may or may not have comorbidities.

Locations
Other Locations
United Kingdom
University of Oxford
RECRUITING
Oxford
Contact Information
Primary
Betty Raman, MBBS, DPhil, FRACP
betty.raman@cardiov.ox.ac.uk
01865234580
Time Frame
Start Date: 2020-05-13
Estimated Completion Date: 2026-05-01
Participants
Target number of participants: 750
Treatments
Non-COVID
We will enrol age, gender, BMI and co-morbidity matched non-COVID control subjects (no serological evidence of previous infection, or active/previous symptoms suggestive of COVID-19). A minimum of 200 controls (as part of the COSMIC study) will be recruited.
COVID-19
Hospitalised patients with moderate to severe infection (admitted for at least 2 days in hospital).
Related Therapeutic Areas
Sponsors
Leads: University of Oxford

This content was sourced from clinicaltrials.gov